Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based Vice President operating in the Pharmaceutical space. If you think a Vice President is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Jeanne Bolger
Vice President Venture Investing of Johnson & Johnson Development Corporation
Jeanne Bolger, MB BCh BAO, Vice President, Venture Investments, joined Johnson & Johnson Development Corporation (JJDC) in 2013. She is based in London, UK. Dr. Bolger has over 25 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development (BD). She spent 11 years in Licensing and Acquisition (L&A), most recently as Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, having joined Johnson & Johnson in 2005 from the Business Development group at GlaxoSmithKline. In 2009, Dr. Bolger became Vice President, Alliance Management at Janssen Alzheimer Immunotherapy, working with Pfizer and Elan. Dr. Bolger received her medical degree from University College Dublin. She also holds diplomas in Child Health (NUI) and in Finance and Accounting (ACCA). She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI). Dr. Bolger has served as the sole pharma industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres. She is a visiting lecturer on the MSc Pharmaceutical Medicine curriculum at Trinity College in Dublin, Ireland.
Follow Jeanne Bolger:
About Johnson & Johnson Development Corporation, Pulmocide: Johnson & Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Alun McCarthy
Vice President of C4X Discovery
Alun has over 30 years of pharmaceutical industry experience, including drug discovery & development, genetics and biomarker research. Alun was co-founder and CEO of both Adorial (in 2014) and of PGXIS (in 2007). Former roles at GlaxoSmithKline include Head of Translational Medicine & Genetics for Psychiatry, Director of Clinical Pharmacogenetics, and Medical Strategy Head for CV/Metabolic Diseases. Alun has managed staff on a global basis, and has significant experience of engaging with regulatory authorities in the US, Europe and Japan. He holds a BA (Biochemistry) from the University of Cambridge, and a PhD (Biochemistry) from Trinity College, Dublin.
Follow Alun McCarthy:
About C4X Discovery: C4X Discovery brings a new dimension to drug discovery. Using its unique NMR-based technique to determine 3D molecular.
Martin Watson
Vice President of C4X Discovery
Martin was one of the first employees of the Company, coming from AstraZeneca plc where he had worked for 4 years in the industrial application of NMR to drug discovery. He has a first class masters chemistry degree from the University of Birmingham and a PhD from the University of Sheffield. He has applied NMR techniques across a wide range of drug targets.
Follow Martin Watson:
About C4X Discovery: C4X Discovery brings a new dimension to drug discovery. Using its unique NMR-based technique to determine 3D molecular.
Victoria Kitcatt
Vice President and Assistant General Counsel of Pfizer
Follow Victoria Kitcatt:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Martin Ducker
Vice President of Juvenescence
Follow Martin Ducker:
About Juvenescence: Juvenescence is a biotech company that develops therapies and products to modify aging and help people live longer.
Martin Lachs
Vice President Global Project Management of ICON plc
Follow Martin Lachs:
About ICON plc: ICON is a global provider of outsourced drug development services to biopharma, medical device, biosimilar and generic organizations.
Christopher Vann
Senior Vice President, Chief Operating Officer of Autolus
Christopher Vann leads commercial activities for Autolus. An industry veteran with 30 years’ experience in both development and business roles, he joined Autolus from Hoffmann-La Roche’s Swiss headquarters, where he was latterly responsible for leading the lung cancer commercial team and general management of the Tarceva brand. He has extensive experience of global lifecycle management of oncology products as well as implementing marketing strategy at a regional and national level. This includes launching several oncology, immunology and transplant products in countries such as China, Japan, Romania, Russia, South Africa, the UK and the USA. He gained his degree in toxicology and pharmacology from the School of Pharmacy, University of London.
Follow Christopher Vann:
About Autolus: Autolus is in T-cell programming and manufacturing technology.
Arif Shivji
Senior Vice President, Business and Corporate Development and Development Operations of Drugabilis
Dr Shivji is a co-founder of Ziarco and was previously Vice President of Development Operations and Business Development. Dr Shivji has a broad experience of drug discovery, development and commercialization and has contributed to bringing 10 commercially available products to the market, through various leadership roles in pharmaceutical sciences and global project management. Prior to Ziarco, he was in Pfizer’s Business Development group. In this role, he was responsible for in-licensing, out-licensing and research collaborations with universities, medical research institutions, governments and companies for Pfizer’s Allergy and Respiratory and Anti-Infectives businesses. Dr Shivji has a degree in Pharmacy, and a PhD in Biophysics from the University of Nottingham, under the direction of Professors’ Martyn Davies, Saul Tendler, Clive Roberts and Phil Williams. His post doctoral research was sponsored by Glaxo SmithKline (GSK) Pharmaceuticals and focussed on understanding the role and mechanism of beta amyloid deposition in Alzheimer’s Disease. Dr Shivji has authored and co-authored a number of scientific papers, abstracts and patents and regularly contributes to scientific and business development meetings. He is currently also a visiting professor at the University of Reading.
Follow Arif Shivji:
About Drugabilis: Drugabilis specializes in solid form characterisation and formulation development for human and animal health.
Nick Child
Vice President of Stablepharma Ltd
Nick Child – Vice President & Co Founder Experienced company leader, business developer, multi-disciplined & experienced in UK & International markets, manufacturing & distribution. Initiated various start-ups, acquisitions, & funding rounds.
Follow Nick Child:
About Stablepharma Ltd: An innovative Biotech, developing a wide range of reformulated thermostable and fridge free StablevaX vaccines
Nicholas Lakin
Vice President, Advisory Services of Kinapse
Follow Nicholas Lakin:
About Kinapse: Kinapse provides advisory, capability building and operational services to the life sciences industries.
